Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Will Biogen (BIIB) Beat Estimates This Earnings Season?

Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.

Sage and Biogen's NDA for Depression Drug Gets Priority Review

Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.

Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know

Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.

Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.

Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.

Andrew Rocco headshot

This "Golden" Technical Indicator is Triggering Across the Market

A Golden Cross is a simple, yet effective technical indicator. Andrew Rocco explains how to use it and relates it back to the current market.

Biogen Inc. (BIIB) Stock Moves -0.02%: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $291.88, marking a -0.02% move from the previous day.

Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again

Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug

The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $280.13, moving -1.18% from the previous trading session.

Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan

Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.

Prothena (PRTA) Stock Gains 88.5% in 6 Months: What Lies Ahead?

Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.

Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know

Biogen Inc. (BIIB) closed at $288.08 in the latest trading session, marking a +1.07% move from the prior day.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe

Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen Inc. (BIIB) closed at $274.72 in the latest trading session, marking a -1.62% move from the prior day.

Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's

FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.

Should iShares Morningstar MidCap Value ETF (IMCV) Be on Your Investing Radar?

Style Box ETF report for IMCV

Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device

Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen Inc. (BIIB) closed at $272.63 in the latest trading session, marking a -1.55% move from the prior day.

Biogen Inc. (BIIB) Stock Moves -0.27%: What You Should Know

Biogen Inc. (BIIB) closed at $274.04 in the latest trading session, marking a -0.27% move from the prior day.

Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma

Following the FDA's approval, Roche (RHHBY) Lunsumio is the first CD20xCD3 T-cell engaging bispecific antibody approved to treat follicular lymphoma.

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

Biogen Inc. (BIIB) closed at $286.86 in the latest trading session, marking a -0.23% move from the prior day.